GT Biopharma shares are trading higher after the company announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550.

Benzinga Newsdesk www.benzinga.com Positive 95.2%

Neg 0% Neu 0% Pos 95.2%

Comments

No comments yet. Be the first!